Breaking AI & Tech News Analyzed

The AI Startup Valuation ShiftAnthropic has usurped OpenAI as the world's most valuable artificial intelligence startup, soaring to a $965bn valuation ahead of expected public listings by the rival firms. Anthropic, the maker of the Claude family of chatbots, said on Thursday that it had raised $65bn from private investors after a fundraising round led by Altimeter Capital, Greenoaks, Dragoneer and Sequoia Capital.Funding and Leadership PositionThe announcement catapults Anthropic, led by CEO and cofounder Dario Amodei, ahead of ChatGPT maker OpenAI in value, which attracted an $852bn valuation in its last fundraising round in March. "This funding will help us serve the historic demand we are experiencing, stay at the research frontier, and bring Claude to more of the places where work happens," Anthropic's Chief Financial Officer Krishna Rao said in a statement.Market Recognition and AdoptionAltimeter Capital CEO Brad Gerstner hailed the adoption of Claude among the "world's most demanding organisations" as evidence of Anthropic's command in the field. "This momentum positions Anthropic to lead the next phase of AI innovation and capture the enormous opportunity ahead," Gerstner said.Rapid Growth and Market PositionFounded in 2021 by former OpenAI researchers, Anthropic has rapidly emerged as one of the leading players in Silicon Valley's scramble to dominate AI. Anthropic's Claude, first launched in 2023, is among the most popular AI models worldwide. In March, the San Francisco-based company said that the chatbot was receiving more than 1 million new sign-ups each day.Challenges and Recent DevelopmentsWhile achieving stellar success in rapid time, Anthropic has also faced challenges – in particular, a high-profile dispute with US President Donald Trump's administration, which has labelled the firm a "supply chain risk" over its refusal to allow unrestricted access to its tools for military purposes. Anthropic unveiled its latest iteration of Claude, Opus 4.8, in a separate announcement on Thursday, calling it a "modest but tangible improvement" on its predecessor.Future Outlook and Market DynamicsAnthropic, OpenAI and Elon Musk's rocket company SpaceX are all expected to go public in the near future in what are expected to be among the biggest initial public offerings in history. Jay R Ritter, an emeritus professor at the University of Florida who specialises in IPOs, said Anthropic has generated a lot of market excitement due to its widespread use by companies for software coding. "This is a big market where apparently Anthropic has the best product," Ritter told Al Jazeera.Valuation Trends and Market Analysis"The increase in valuation in a short period of time is unprecedented for a startup, although publicly traded tech companies such as SK Hynix, Nvidia, and Alphabet have seen even bigger increases, although not as much in percentage terms," Ritter said, referring to the South Korean and US chip giants, and Google's parent company. While it remains to be seen whether the massive investments pouring into AI are creating a bubble, Ritter said, the handful of successful firms that are likely to emerge in the field could see enormous profits.Industry Consolidation and Future Prospects"Nobody wants to use the eighth best product, so these companies are either one of the handful of successful firms, or they will have a zero market share," he said. "The tech industry is different than the restaurant industry, where there are not large economies of scale, and where competition limits the profit margins."

The LeadExeter Chiefs delivered a stunning performance at Welford Road, becoming the first away side to defeat Leicester Tigers in the league at their fortress home in 14 months. The 35-26 victory was secured through two tries from veteran full-back Olly Woodburn, whose performance proved decisive in ending the Tigers' unbeaten run.The Event DetailsThe match was a ferocious contest from start to finish, with both teams demonstrating their championship credentials. Exeter's strategy focused on disrupting Leicester's set-piece and implementing punishing defense around the ruck, while their attack was led by the powerful wing Manny Feyi-Waboso, who carved through the Tigers' defense to set up Woodburn's first try in the seventh minute.Leicester responded with a try from 20-year-old academy full-back George Pearson on his first Premiership start, but Exeter regained the lead early in the second half through tries from Len Ikitau and Woodburn's second score. Despite Woodburn being sin-binned and Leicester fighting back to take a one-point lead, Exeter dug deep to score through second row Andrea Zambonin and seal the victory with Slade's late penalty.The Impact AnalysisThis victory represents a significant turnaround for Exeter Chiefs, who just last season languished in ninth place out of ten in the Premiership. Director of rugby Rob Baxter has masterminded this resurgence, and this win at one of the league's most difficult away venues will provide tremendous confidence as they head into their final regular season match.For Leicester, the defeat ends their remarkable unbeaten run at home and represents a momentum stopper as they prepare for the playoffs. While they remain firmly in the playoff positions, the loss will raise questions about their ability to perform under pressure in crucial matches.The PredictionExeter will now approach their final regular season match against Saracens at Sandy Park with renewed belief. A victory there would secure their place in the playoffs, and based on this performance against a top-four side, they have every chance of achieving that goal.Leicester, already assured of a playoff spot, will need to regroup quickly ahead of their trip to Bath. With home advantage in the semi-finals potentially at stake, they'll be determined to secure a victory and maintain their championship aspirations.

The Lead: Iran's Energy Recovery After AttacksIran has restored gas production at three offshore platforms in the South Pars gasfield, the world's largest natural gasfield, after it was attacked by Israel in March. The resumption of operations comes amid ongoing tensions in the region and continued negotiations with the United States over a potential deal to end the conflict.Technical Recovery at South Pars GasfieldTouraj Dehqani, head of the Pars Oil and Gas Company, confirmed that the three platforms were not damaged in the Israeli attacks and that production is being rerouted to other processing plants in the region while repairs continue at damaged facilities. The South Pars gasfield, located off the coast of Iran's southern Bushehr province, spans 9,700sq km and is shared between Iran and Qatar, with the Iranian side known as South Pars and the Qatari side called the North Field.Economic Impact of Production ResumptionThe restoration of gas production at South Pars is significant both symbolically and practically for Iran's economy. As the country's largest source of domestic energy, the facility plays a crucial role in Iran's ability to generate electricity and maintain energy security. The resumption of operations represents an important first step forward, though challenges remain in fully restoring export capabilities amid ongoing US port blockades and sanctions.Regional Energy Security ImplicationsThe Israeli attacks on South Pars in mid-March and on Iran's largest petrochemical facility in early April prompted retaliatory Iranian missile and drone strikes on energy infrastructure across the wider region. These attacks have highlighted the vulnerability of energy infrastructure in the Middle East and the potential for regional conflicts to disrupt global energy markets. The resumption of production at South Pars sends a message of resilience but also underscores the precarious nature of energy security in the region.Future Outlook Amid Ongoing TensionsAs negotiations between Washington and Tehran continue, Iran's chief negotiator has stated that Tehran will not agree to any deal with Washington unless it secures Iran's full rights. The US President's administration has maintained a blockade of Iranian ports as part of a pressure campaign. While the reopening of South Pars is a positive development, the long-term sustainability of Iran's energy sector depends on resolving both internal challenges and external pressures, particularly the US sanctions and regional tensions that continue to impact the country's ability to fully utilize its energy resources.

Liverpool's Managerial Search Liverpool will hold formal talks with Andoni Iraola over their managerial vacancy this week and hope to install Arne Slot's successor before the World Cup begins. Iraola as the Frontrunner Liverpool are planning to move quickly in their search for a new head coach and intend to speak to their preferred candidates at the earliest opportunity. Contact has been made with Iraola's camp and formal talks are expected over the coming days. The club are also likely to sound out Stuttgart's Sebastian Hoeness and Pierre Sage, of Lens, but the former Bournemouth head coach, who was brought to the south coast by Liverpool's sporting director, Richard Hughes, is the frontrunner to replace Slot. The Need for a Swift Appointment Milan, Bayer Leverkusen and Crystal Palace have all made approaches to Iraola since he left Bournemouth after three impressive seasons, his final campaign delivering European football to the Vitality Stadium for the first time. There could also be rival interest in Sage from Palace. Liverpool, therefore, need to act swiftly and want to conclude the entire process before the World Cup starts on 11 June to give the new man ample time to prepare. Compensation and Contract Status That schedule also enhances Iraola's claims. Liverpool would have to pay compensation to extract Hoeness, Sage or another employed coach from their current clubs whereas the 43-year-old Basque is out of contract and available now. Background on Slot's Departure Slot was informed his Liverpool career was over approximately 90 minutes before the club announced their decision at 12.30pm on Saturday. He was sacked following a review into Liverpool's troubled season that was led by Hughes and Michael Edwards, chief executive of football at the club's owner, Fenway Sports Group. FSG continues to back the pair to lead Liverpool's football operation despite the disappointing return on last summer's outlay on new signings of almost £450m.

The Proposed Pay Scheme The chief executive of Arm is in line for a pay package that would make him a billionaire if he hits targets to turn the British microchip giant into the UK's first trillion-dollar company. Arm, which is listed in New York but retains its global headquarters in Cambridge, has proposed a pay scheme for Rene Haas in which he will receive generous annual share awards plus a maximum bonus of $800m if he can hit certain 'exceptional growth metrics'. The Targets In the proposed bonus, or 'value creation plan' for Haas, 63, he will be awarded 425,000 shares if he can hit targets. The first target is a trillion-dollar valuation by 2029, reaching $1.25trn the following year and £2trn by the end of March 2031. The Financial Impact The payout would be one of the biggest ever awarded by a British company. Assuming the policy is approved and the targets are hit, Haas is in line to make well over $1bn in total by 2031. Maximum bonus: $800m Annual award of shares: up to 200% of salary Targets: $1 trillion valuation by 2029, $1.25trn by 2030, and £2trn by 2031 The Industry Impact The eye-watering market capitalisation-based pay schemes increasingly being offered by US companies dwarf the level of rewards at UK businesses. This deal highlights the competitive nature of executive remuneration in the global technology industry. The Future Outlook Haas, who is pushing Arm from its core strategy of providing architecture for microchips in smartphones into developing chips for AI datacentres, has predicted that this change of tack could increase Arm's revenues fivefold.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Landmark Broadcasting Deal CBS Sports has secured a four-year deal to broadcast the Women’s Super League (WSL) live in the US, starting from the next season and running until the end of the 2029-30 campaign. This deal represents a significant increase in valuation, potentially bringing in a fourfold increase in revenue for the WSL compared to previous seasons. Broadcasting Details Under the new agreement, the Paramount+ streaming service will air 183 WSL matches per season. Additionally, the CBS Sports Network will show one live match per week, with select matches also airing on the CBS Sports Golazo Network. This deal was negotiated by IMG, the international media rights representative for WSL Football. The Impact on Women's Football This deal marks a new record high for a US broadcasting agreement in the WSL. CBS Sports already holds rights to other women’s leagues, including the NWSL and the Women’s Champions League. The network had previously held WSL rights during the 2023-24 season. Zarah Al-Kudcy, WSL Football’s chief revenue officer, expressed excitement about welcoming CBS Sports back, highlighting their commitment to women’s football and their extensive talent roster. The Future of WSL Broadcasting The deal was finalized much earlier than previous agreements, which were typically announced shortly before the start of the season. This early conclusion brings stability and excitement ahead of the next WSL season in September. The partnership also comes as several WSL players have been named to the US women’s national team roster, further boosting the league’s profile.

Sky announced it will exit its 24‑hour Arabic news joint venture with the United Arab Emirates, Sky News Arabia, following intense criticism over the channel’s coverage of the Sudan war and accusations of genocide denial. Under a new commercial agreement, Sky will give up all strategic and operational control but will continue to license the Sky News brand to the outlet. Strategic Withdrawal and New Licensing Arrangement The exit sees Sky handing over full ownership to IMI, the investment vehicle controlled by Sheikh Mansour bin Zayed al‑Nahyan, UAE vice‑president and Manchester City owner. In a statement, David Rhodes, executive chairman of Sky News Group, said the partnership had built a significant regional presence and that the timing was right for a change. IMI will now steer the platform’s future, while Sky secures a multi‑year brand‑licensing deal that lets the channel retain the Sky News Arabia name. Timeline of Sky News Arabia’s Decade‑Long Presence 2010: Channel launched in Abu Dhabi as a rival to Al‑Jazeera and BBC Arabic. 2012: Joint venture began broadcasting across the Middle East and North Africa. November 2025: Sudanese government banned the channel after a report claimed stability in El Fasher. February 2026: UN fact‑finding mission identified “hallmarks of genocide” in the RSF siege of El Fasher. May 2026: Sky announces exit and new licensing deal. Reputational and Regional Implications of the Sudan Coverage Controversy Internal Sky executives grew uneasy about the editorial line taken by Sky News Arabia, which was accused of whitewashing atrocities committed by the UAE‑backed Rapid Support Forces (RSF). Specific concerns included a report that downplayed the humanitarian crisis and the fact that the channel’s reporter in El Fasher was married to a senior RSF official. The controversy prompted Sudan to ban the channel and heightened scrutiny of the venture’s credibility across the Arab world. Future Outlook for Sky’s Middle‑East Footprint Nakhle ElHage, chief transformation officer at IMI, said the next phase will focus on building the platform into the leading multi‑media news destination for the Arab world. For Sky, the move mirrors a similar decision in Australia, where a licensing agreement for the Sky News brand is ending and the channel will rebrand as News24. The brand‑licensing arrangement allows Sky to maintain a presence without direct editorial responsibility, while IMI gains full control to shape content and investment strategy.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."